Table 2.
Phase III trials evaluating the role of adjuvant chemotherapy in grade II and III gliomas.
| Whole cohort |
IDH-mutant (all) |
IDH-mutant, 1p/19q codeleted |
IDH-mutant, 1p/19q non-codeleted |
IDH-wild type |
|||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS (yrs) | HR (95% CI) | p value | OS (yrs) | HR (95% CI) | p value | PFS (yrs) | HR (95% CI) | p value | OS (yrs) | HR (95% CI) | p value | PFS (yrs) | HR (95% CI) | p value | OS (yrs) | HR (95% CI) | p value | PFS (yrs) | HR (95% CI) | p value | OS (yrs) | HR (95% CI) | p value | PFS (yrs) | HR (95% CI) | p value | OS (yrs) | HR (95% CI) | p value | ||
| Diffuse low-grade gliomas (WHO grade II) | |||||||||||||||||||||||||||||||
| RTOG 980236 | RT (n = 126) | 4.0 | 1 | <0.001 | 7.8 | 1 | 0.003 | ≈ 4.6 | 1 | <0.001 | ≈ 10.1 | 1 | 0.02 | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na |
| High-risk grade II gliomas | RT + PCV (n = 125) | 10.4 | 0.50 (0.36–0.68) | 13.3 | 0.59 (0.42–0.83) | NR | 0.32 (0.17–0.62) | NR | 0.42 (0.20–0.86) | na | na | na | na | na | na | na | na | na | na | na | na | ||||||||||
| EORTC 2203322 | RT (n = 240) | 3.8 | 1 | 0.22 | na | na | na | na | na | na | na | na | na | ≈ 5.0 | 1 | 0.91 | na | na | na | ≈ 4.6 | 1 | 0.0043 | na | na | na | ≈ 1.6 | 1 | 0.24 | na | na | na |
| High-risk grade II gliomas | TMZ (n = 237) | 3.3 | 1.16 (0.9–1.5) | na | na | na | na | na | na | ≈ 4.5 | 1.04 (0.56–1.93) | na | na | ≈ 2.9 | 1.86 (1.21–2.87) | na | na | ≈ 2.1 | 0.67 (0.34–1.32) | na | na | ||||||||||
| Anaplastic gliomas (WHO grade III) | |||||||||||||||||||||||||||||||
| EORTC 2695120 | RT (n = 183) | 1.1 | 1 | na | 2.6 | 1 | na | 3.0 | 1 | na | 5.4 | 1 | na | 4.2 | 1 | na | 9.3 | 1 | na | na | na | na | na | na | na | 0.6 | 1 | na | 1.2 | 1 | na |
| Anaplastic oligodendrogliomas | RT + PCV (n = 185) | 2.0 | 0.66 (0.52–0.83) | 3.5 | 0.75 (0.60–0.95) | 5.9 | 0.49 (0.29–0.84) | NR | 0.53 (0.30–0.95) | 13.1 | 0.42 (0.24–0.74) | NR | 0.56 (0.31–1.03) | na | na | na | na | 0.8 | 0.56 (0.37–0.86) | 1.6 | 0.78 (0.52–1.18) | ||||||||||
| RTOG 940221,37,38 | RT (n = 143) | 1.7 | 1 | 0.004 | 4.6 | 1 | 0.1 | na | na | na | 5.7 | 1 | 0.006 | 2.9 | 1 | <0.001 | 6.8 | 1 | 0.01 | na | na | na | 3.3 | 1 | 0.045 | na | na | na | 1.8 | 1 | 0.67 |
| Anaplastic oligodendrogliomas | RT + PCV (n = 148) | 2.6 | 0.69 (0.52–0.91) | 4.7 | 0.79 (0.60–1.04) | na | na | 9.4 | 0.59 (0.40–0.86) | 8.4 | 0.47 (0.30–0.72) | 14.7 | 0.49 (0.28–0.85) | na | na | 5.5 | 0.56 (0.32–0.99) | na | na | 1.3 | 1.14 (0.63–2.04) | ||||||||||
| CATNON39 | RT, no adj TMZ (n = 372) | 1.6 | 1 | na | 3.4 | 1 | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na |
| Non-codeleted anaplastic gliomas | RT + adj TMZ (n = 373) | 3.6 | 0.62 (0.50–0.76) | NR | 0.65 (0.45–0.93) | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | na | ||||||||||
adj, adjuvant; HR, hazard ratio; na, not available; NR, not reached; OS, overall survival; PCV, procarbazine, lomustine and vincristine; PFS, progression-free survival; RT, radiotherapy; TMZ, temozolomide; yrs, years.